MiNK Therapeutics (NASDAQ:INKT) CEO Jennifer Buell Sells 6,938 Shares of Company Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) CEO Jennifer Buell sold 6,938 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $10.56, for a total transaction of $73,265.28. Following the transaction, the chief executive officer owned 74,195 shares of the company’s stock, valued at $783,499.20. This trade represents a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $10.35 on Thursday. The company has a 50-day moving average of $11.60 and a two-hundred day moving average of $11.47. MiNK Therapeutics, Inc. has a 12-month low of $8.48 and a 12-month high of $16.93.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02). On average, equities research analysts expect that MiNK Therapeutics, Inc. will post -1.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on INKT. Zacks Research lowered MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company’s research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.

The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors.